Triple-M syndrome after immune checkpoint inhibitors: a systematic review of cases-early recognition is critical to survival.

What was studied

This review looked at triple-M syndrome after immune checkpoint inhibitor cancer drugs. It is an overlap of myositis, myocarditis and myasthenia gravis. The team reviewed case reports and case series up to July 2025. They described features, test results, treatments and outcomes.

What they found

The syndrome began early after the drug was started. Signs were fast and varied. They included eye and throat symptoms, and muscle and heart problems. Routine tests were often not sensitive, so diagnosis was hard. High-dose steroids were the most common first treatment, often with immunoglobulins or plasma exchange. Steroids alone were tied to worsening in some cases. Outlook was poor. Breathing failure was common, and so was cancer progression after stopping treatment.

What it means for patients

The authors say triple-M is a severe complication that is often missed. They say it needs early diagnosis and fast team-based care. They say more work must improve diagnosis and treatment while keeping the cancer benefit.

Why it is not certain yet

The evidence comes from case reports and case series. These cannot show how common the syndrome is. The abstract does not give the number of cases. New therapies were only said to have potential.

Source

Triple-M syndrome after immune checkpoint inhibitors: a systematic review of cases-early recognition is critical to survival.

We restate facts from the source record in our own words. The original wording belongs to its publisher.